Nomura Holdings Inc. Buys 34,308 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Nomura Holdings Inc. boosted its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 187.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 52,607 shares of the company's stock after acquiring an additional 34,308 shares during the period. Nomura Holdings Inc. owned 0.09% of Harmony Biosciences worth $1,810,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of HRMY. Swiss National Bank grew its position in shares of Harmony Biosciences by 28.2% in the fourth quarter. Swiss National Bank now owns 78,200 shares of the company's stock valued at $2,691,000 after purchasing an additional 17,200 shares during the last quarter. Teacher Retirement System of Texas raised its holdings in shares of Harmony Biosciences by 50.6% in the 4th quarter. Teacher Retirement System of Texas now owns 11,801 shares of the company's stock worth $406,000 after purchasing an additional 3,964 shares during the period. Vanguard Group Inc. raised its holdings in Harmony Biosciences by 36.4% in the fourth quarter. Vanguard Group Inc. now owns 4,733,609 shares of the company's stock valued at $162,883,000 after buying an additional 1,262,362 shares during the period. Barclays PLC boosted its position in Harmony Biosciences by 110.9% during the 3rd quarter. Barclays PLC now owns 76,862 shares of the company's stock worth $3,074,000 after purchasing an additional 40,416 shares during the period. Finally, Amundi lifted its stake in shares of Harmony Biosciences by 243.3% during the fourth quarter. Amundi now owns 18,402 shares of the company's stock worth $635,000 after purchasing an additional 13,041 shares in the last quarter. Institutional investors and hedge funds own 86.23% of the company's stock.

Harmony Biosciences Stock Down 0.6%

Harmony Biosciences stock traded down $0.20 during trading hours on Friday, hitting $33.93. The company had a trading volume of 61,824 shares, compared to its average volume of 597,776. The firm's fifty day moving average is $31.59 and its 200-day moving average is $34.01. The firm has a market capitalization of $1.95 billion, a P/E ratio of 16.09, a price-to-earnings-growth ratio of 0.47 and a beta of 0.82. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $26.47 and a fifty-two week high of $41.61. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.19. The business had revenue of $184.73 million during the quarter, compared to analyst estimates of $184.26 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The firm's revenue was up 19.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.67 EPS. On average, research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on HRMY. HC Wainwright restated a "buy" rating and issued a $70.00 target price on shares of Harmony Biosciences in a research note on Tuesday, April 8th. Cantor Fitzgerald upgraded Harmony Biosciences to a "strong-buy" rating in a research report on Tuesday, May 13th. Mizuho boosted their price objective on shares of Harmony Biosciences from $44.00 to $48.00 and gave the company an "outperform" rating in a research report on Thursday, May 15th. Needham & Company LLC reaffirmed a "buy" rating and issued a $49.00 target price on shares of Harmony Biosciences in a research report on Tuesday, May 6th. Finally, UBS Group dropped their price target on shares of Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating on the stock in a research note on Monday, April 28th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $52.78.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.